News Focus
News Focus
icon url

Amatuer17

06/28/20 7:41 AM

#256606 RE: Investor2014 #256603

Typically if the topline data is good, companies issue in a hurry and then keep more detailed analysis for a conference.

This also allows them to go to FDA requesting meeting while they do all the analysis.

They will need the next level details to justify that the results are good if the general topline results are not good or very good.